LV10308A - Ciliarais neirotropais faktors - Google Patents

Ciliarais neirotropais faktors

Info

Publication number
LV10308A
LV10308A LV930441A LV930441A LV10308A LV 10308 A LV10308 A LV 10308A LV 930441 A LV930441 A LV 930441A LV 930441 A LV930441 A LV 930441A LV 10308 A LV10308 A LV 10308A
Authority
LV
Latvia
Prior art keywords
cntf
nucleic acid
acid sequences
relates
variety
Prior art date
Application number
LV930441A
Other languages
English (en)
Latvian (lv)
Inventor
Piotr Masiakowski
Vivien Wong
Nikos Panayotatos
Hans Friedrich Erwin Thoenen
Kurt A Stockli-Rippstein
Michael Sendtner
Yoshihiro Arakawa
Patrick Desmond Carroll
Rudolf George Gotz
George W Kreutzberg
Dan B Lindholm
Friedrich Lottspeich
Nancy Ip
Mark E Furth
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of LV10308A publication Critical patent/LV10308A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LV930441A 1989-09-15 1993-05-31 Ciliarais neirotropais faktors LV10308A (lv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40817289A 1989-09-15 1989-09-15
US42951789A 1989-10-31 1989-10-31
US57065190A 1990-08-20 1990-08-20
PCT/US1990/005241 WO1991004316A2 (en) 1989-09-15 1990-09-14 Ciliary neurotrophic factor

Publications (1)

Publication Number Publication Date
LV10308A true LV10308A (lv) 1994-10-20

Family

ID=27410749

Family Applications (1)

Application Number Title Priority Date Filing Date
LV930441A LV10308A (lv) 1989-09-15 1993-05-31 Ciliarais neirotropais faktors

Country Status (11)

Country Link
US (1) US6602687B1 (es)
EP (1) EP0448707B1 (es)
JP (2) JPH05199879A (es)
AT (1) ATE130365T1 (es)
AU (1) AU705371B2 (es)
CA (1) CA2040404A1 (es)
DE (1) DE69023637T2 (es)
ES (1) ES2084045T3 (es)
IE (1) IE903130A1 (es)
LV (1) LV10308A (es)
WO (1) WO1991004316A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405835B (de) * 1989-01-05 1999-11-25 Synergen Inc Aufgereinigter ziliärer neurotropher faktor
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
IL98304A (en) * 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor
IT1247150B (it) * 1991-01-21 1994-12-12 Fidia Spa Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
CN1065768C (zh) * 1991-07-10 2001-05-16 里珍纳龙药品有限公司 应用bdnf/nt-3/ngf分子族成员治疗运动神经元疾病的方法
HUT67352A (en) * 1991-07-23 1995-03-28 Syntex Inc Recombinant ciliary neurotrophic factor and c-ferminal truncated ciliary neurotrophic factor, their production, and pharmaceutical products for treatment of peripheral nerveinjury, containing them
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1993007270A1 (en) * 1991-10-01 1993-04-15 Genentech, Inc. Production of gpa neurotrophic factor
AU2925392A (en) * 1991-11-11 1993-06-15 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
AU6169894A (en) * 1993-02-08 1994-08-29 Syntex-Synergen Neuroscience Joint Venture, The Methods for treating amyotrophic lateral sclerosis with cntf
AU6284194A (en) * 1993-03-12 1994-09-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
TW248552B (es) 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
EP0999270A1 (en) * 1998-10-09 2000-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of regulating SMN gene expression
CA2409956A1 (en) * 2000-05-24 2001-11-29 Regeneron Pharmaceuticals, Inc. Use of ciliary neurotrophic factor
EP1458888B1 (en) * 2001-12-10 2011-03-30 Novartis AG Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene
JP2005073592A (ja) * 2003-09-01 2005-03-24 Yukiguni Maitake Co Ltd マイタケ由来のレクチンをコードする遺伝子
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
KR102318706B1 (ko) * 2013-12-11 2021-10-28 스미또모 가가꾸 가부시끼가이샤 모양체 주연부-유사 구조체의 제조 방법
EP3810083A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-? (tnf-?) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease
EP4076495A4 (en) * 2019-12-18 2023-12-20 Cella Therapeutics, LLC DRUG DELIVERY SYSTEMS INCLUDING NEUROTROPHIC AGENT, APOPTOSIS SIGNALING FRAGMENT (FAS) INHIBITOR OR FAS LIGAND INHIBITOR (FASL), TUMOR NECROSIS FACTOR INHIBITOR? (TNF-A) OR TNF RECEPTOR, MITOCHONDRIAL PEPTIDE, OLIGONUCLEOTIDE, CHEMOKINE INHIBITOR OR ASPARTIC CYSTEINE PROTEASE INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
AU5341790A (en) * 1989-03-15 1990-10-09 Regents Of The University Of California, The Purified ciliary neurotrophic factor
KR910016921A (ko) * 1990-03-14 1991-11-05 파디아 에스. 피. 에이 인간의 모양체 신경원영양 인자, 그를 코딩하는 dna 서열 및 재조합 기술에 의한 그의 제조방법

Also Published As

Publication number Publication date
DE69023637D1 (de) 1995-12-21
CA2040404A1 (en) 1991-03-16
EP0448707A1 (en) 1991-10-02
EP0448707A4 (en) 1992-11-19
WO1991004316A3 (en) 1991-04-18
WO1991004316A2 (en) 1991-04-04
EP0448707B1 (en) 1995-11-15
AU705371B2 (en) 1999-05-20
US6602687B1 (en) 2003-08-05
ES2084045T3 (es) 1996-05-01
JP2001354697A (ja) 2001-12-25
ATE130365T1 (de) 1995-12-15
JPH05199879A (ja) 1993-08-10
DE69023637T2 (de) 1996-10-17
AU6740290A (en) 1991-04-18
IE903130A1 (en) 1991-03-27

Similar Documents

Publication Publication Date Title
LV10308A (lv) Ciliarais neirotropais faktors
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
SI0852585T1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
FI912104A0 (fi) Neurotrofisk faktor haerledd fraon hjaerna.
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3685885D1 (de) Oligopeptide sowie zwischenprodukte und verfahren zu ihrer herstellung.
ATE17858T1 (de) Angiotropine aus leukozyten und entzuendeten geweben: eine neue klasse von natuerlichen chemotropischen und mitogenen proteinen fuer die spezifische induktion des gesteuerten wachstums von blutgefaessen, fuer neue gefaessbildung von geweben und fuer die morphogenese von blutgefaessverzweigungen; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
EP0458673B1 (en) Growth-inhibitory factor and cDNA coding for growth inhibitory factor
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
ATE61222T1 (de) Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels.
JPH05125097A (ja) 神経細胞およびグリア細胞に作用する新規タンパクおよびそれを含有する医薬品